Criminal Prosecution of Novo Nordisk
In June 2011, Novo Nordisk paid $25 million to resolve allegations that it engaged in off-label promotion of NovoSeven, a recombinant biologic drug that is FDA approved to treat hemophilia. The United States alleged that Novo Nordisk paid military physicians remuneration for questionable research to support and promote the use of NovoSeven for use in trauma-related hemorrhage, even in the face of mounting evidence of harm. As part of the settlement, the defendant has agreed to enter into an expansive Corporate Integrity Agreement (CIA) with HHS/OIG.
Source: HHS Health Care Fraud and Abuse Control Program, Annual Report for FY 2011
This article was posted on July 15, 2012.